Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1905298 | 0.81 | OPRL1 (0.42) | VNN1FFAR1ROCK2ROCK1ACACB | |
| SCHEMBL1901967 | 0.81 | FFAR1 (0.39) | VNN1FFAR1ROCK2ROCK1PDE4D | |
| SCHEMBL1905635 | 0.80 | ACACB (0.36) | FFAR1ROCK2ROCK1ACACB | |
| SCHEMBL1903122 | 0.79 | ACACB (0.50) | FFAR1SLC16A3ROCK2ROCK1ACACB | |
| SCHEMBL1899248 | 0.78 | FFAR1 (0.31) | FFAR1OPRM1OPRL1 | |
| SCHEMBL13254923 | 0.77 | SSTR4 (0.42) | VNN1FFAR1DPP4 | |
| SCHEMBL1608427 | 0.76 | VNN1 (0.42) | VNN1DPP4OPRM1OPRL1 | |
| SCHEMBL1900135 | 0.74 | CYP1A2 (0.39) | FFAR1ROCK2ROCK1 | |
| SCHEMBL1902393 | 0.74 | ROCK2 (0.38) | FFAR1ROCK2ROCK1 | |
| SCHEMBL1908154 | 0.74 | TRPV4 (0.38) | VNN1FFAR1ACACBPDE4DOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | VNN1 3559/4885FFAR1 2591/4885SLC16A3 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.